#USA #New York #IDEAYA Biosciences #darovasertib #oncology research

IDEAYA Biosciences 10-Year R&D Day Agenda

IDEAYA Biosciences, Inc., a leader in precision medicine oncology, is thrilled to announce the agenda for its much-anticipated in-person Research and Development (R&D) Day, coinciding with the company’s 10-year anniversary. Scheduled for September 8, 2025, from 8:00 to 10:30 AM EST in New York, this event promises to provide invaluable insights into the company's progress and future directions.

Inspiring Leadership

Members of IDEAYA's senior leadership will take the stage to discuss their significant advancements in developing targeted therapeutics. Attendees can look forward to intriguing presentations that feature new clinical data on key pharmaceutical candidates:

• - Darovasertib (PKC): Attendees will gain insight into the Phase 2 data from the neoadjuvant uveal melanoma trials, focusing on patients eligible for plaque brachytherapy.
• - IDE849 (DLL3 TOP1 ADC): This segment will cover breakthrough Phase 1 data from the 2025 World Conference on Lung Cancer (WCLC), along with mechanistic data supporting the combination of TOP1-ADCs with IDE161/PARG.
• - IDE397 (MAT2A): Presentations will explore the rationale for combining IDE397 with Trodelvy (a TROP2 TOP1 ADC) specifically in context of solid tumors with MTAP deletions. Initial Phase 1 clinical data for this combination in urothelial cancers will also be shared.
• - IDE892 (PRMT5): The agenda will discuss IDE892's potential as a best-in-class PRMT5 therapeutic, highlighting its combination opportunities with IDE397 for treating MTAP-deleted solid tumors.

A Sustainable Future with AI/ML

Another highlight of R&D Day will be the exploration of artificial intelligence and machine learning in enhancing IDEAYA's discovery capacities, an indication of the company's commitment to integration of innovative technologies in oncology research.

Expert Insights

Adding depth to the day, IDEAYA will welcome Dr. Arun D. Singh, a prominent figure in ophthalmic oncology from the Cole Eye Institute, Cleveland Clinic. Dr. Singh will present data from the Phase 2 trial of darovasertib in uveal melanoma, elaborating on the design and objectives of the newly launched Phase 3 OptimUM-10 trial.

Engaging with the Audience

An interactive question-and-answer session will follow the presentations, providing guests with the opportunity to engage directly with IDEAYA’s leadership and guest speakers.

Registration and Access

Anyone interested in attending can register through the IDEAYA website. This is a chance to witness firsthand the innovative work being done in the field of precision oncology and to understand more about IDEAYA's plans for the future.

About IDEAYA Biosciences

IDEAYA Biosciences is dedicated to the discovery, development, and commercialization of transformative cancer therapies that are tailored to the genetic drivers of diseases. Their approach combines expertise in small molecule discovery, structural biology, and bioinformatics, resulting in a strong pipeline focused on synthetic lethality and antibody-drug conjugates, which align with molecularly defined tumor indications. IDEAYA is committed to pioneering the next generation of precision oncology treatments, aiming to deliver innovative therapies that are not only more effective but also deeply personalized.

Forward-Looking Statements

This announcement contains forward-looking statements about IDEAYA's future achievements and growth. The company undertakes no obligation to update or revise these, but encourages stakeholders to keep an eye on upcoming filings with the U.S. Securities and Exchange Commission for comprehensive insights into their operational health.

Conclusion

The 10-year anniversary R&D Day for IDEAYA Biosciences represents both a celebration of past achievements and a look into the future of oncological research. As the landscape of oncology continues to evolve, IDEAYA is positioned at the forefront of innovative therapies that promise to change the lives of cancer patients worldwide.